Seed Innovations Ltd

Food Standard Agency's Public List of CBD Products

RNS Number : 2219H
Seed Innovations Limited
05 April 2022

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

5 April 2022

SEED Innovations Limited ("SEED" or the "Company")

 Food Standard Agency's Public List of CBD Products Update

SEED Innovations Ltd, the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to note the recent update by the UK Food Standard Agency ('FSA') with a list of cannabidiol ('CBD') products permitted to stay on the market in England and Wales, pending further consideration.

A number of CBD products sold by some of SEED's portfolio companies, have successfully been included on the FSA's list of CBD products linked to novel food applications, enabling them to continue in the market and progress through the validation stage.

This follows a two-year cooperation between the FSA and the Association for the Cannabinoid Industry, the UK's CBD sector trade body.

Products from investee companies Yooma Wellness Inc. ('Yooma'), South West Brands Limited ('SWB'), and CiiTECH Limited ('CiiTECH') have been included in the update by the FSA.



· Portfolio companies Yooma, SWB, and CiiTECH have featured on the FSA's list of CBD products that may stay on the market in England and Wales

· Products which appear on the list are linked to novel food applications which the FSA already validated or considered that are sufficiently progressing towards validation

· The UK becomes one of the first countries to regulate the sale of CBD products as foodstuff to consumers



Alfredo Pascual, VP of Investment Analysis of SEED, commented: " We are very encouraged to see the inclusion of a number of our investee companies' products within the FSA's public list of CBD products that may stay on the market in England and Wales. The hard work being carried out by our portfolio companies to meet the UK's legal and regulatory requirements indicates a high level of level of commitment to quality and safety, bringing much needed clarity to consumers. 

"We welcome regulatory certainty in the sector and look forward to further progress as the sector continues to establish itself."


Further  information from the Food Standard Agency can be found at


For further information on the Company please visit or contact:



Ed McDermott

Lance de Jersey

SEED Innovations Ltd

E: [email protected]


James Biddle

Roland Cornish

Beaumont   Cornish   Limited,


T: (0)20 7628 3396


Isabella Pierre

Damon Heath

Shard Capital Partners LLP


T: (0)20 7186 9927

Catherine Leftley

Isabelle Morris

St Brides Partners Ltd,

Financial PR

E: [email protected]




SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.